In this study, we used Herceptin® (trastuzumab), which targets HER2-expressing cancer cells, as a model therapeutic antibody, and quantitatively evaluated the antibody activity in therapeutic antibody-modified NBs upon exposure to TUS to assess the utility of the platform as an antibody-delivery system for cancer therapy (Figure 1). Here, ERBB2 is linked to cancer.